Halda Therapeutics

Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer

Brings proven leadership and successful track record to Halda as the company enters the next stage of growth as clinical-stage company NEW HAVEN, Conn. – Halda Therapeutics, a biotechnology company developing a novel class of cancer therapies called RIPTAC™ (Regulated Induced Proximity TArgeting Chimeras) therapeutics, today announced that it has appointed Christian Schade as President and Chief Executive Officer and a member of the Board of … Continue reading Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer

Luxa Biotechnology

Luxa Biotechnology LLC Appoints Keith E. Dionne, Ph.D., as Chief Executive Officer

FORT LEE, N.J. – Luxa Biotechnology LLC (Luxa), a clinical -stage biotechnology company developing a novel adult retinal pigment epithelial stem cell (RPESC) therapy for dry age-related macular degeneration (AMD), today announced the appointment of Keith Dionne, Ph.D. as Chief Executive Officer. “I am honored to join Luxa at such an exciting time” Post this An early pioneer in the cell therapy field and a … Continue reading Luxa Biotechnology LLC Appoints Keith E. Dionne, Ph.D., as Chief Executive Officer

VedaBio

VedaBio Appoints Randy Rasmussen, Former CEO of BioFire Diagnostics, to Board of Directors

Renowned Molecular Diagnostics Leader Joins as VedaBio Enters its Next Phase of Development SAN DIEGO – VedaBio, a pioneering biotechnology company at the forefront of molecular detection, today announced the appointment of Randy Rasmussen, Ph.D., to its Board of Directors. Dr. Rasmussen, a visionary in the molecular diagnostics field with over 30 years of experience, brings deep industry knowledge to VedaBio as the company advances … Continue reading VedaBio Appoints Randy Rasmussen, Former CEO of BioFire Diagnostics, to Board of Directors

Prothena

Prothena Announces Leadership Team Updates

DUBLIN – Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Chad Swanson, Ph.D., has been appointed Chief Development Officer and will assume leadership of clinical development and medical functions. Chad will join Prothena’s executive leadership team and will report to Gene Kinney, Ph.D., President and Chief Executive Officer. Hideki … Continue reading Prothena Announces Leadership Team Updates

Nextleaf

Nextleaf Announces the Appointment of Chief Executive Officer

September 26, 2024 Vancouver, British Columbia–(Newsfile Corp. – September 26, 2024) – Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) (“Nextleaf”, “OILS”, or the “Company”), a leading life science firm and licensed cannabis processor, is pleased to announce the permanent appointment of Emma Andrews as the Chief Executive Officer of the Company. Appointment of Chief Executive Officer The Board of Directors of the Company (the … Continue reading Nextleaf Announces the Appointment of Chief Executive Officer